| Dr Brent Jeremy Campbell, DO | |
|
1025 Executive Drive, Suite 100, Hixson, TN 37343 | |
| (423) 778-9030 | |
| (423) 778-9031 |
| Full Name | Dr Brent Jeremy Campbell |
|---|---|
| Gender | Male |
| Speciality | Osteopathic Manipulative Medicine |
| Experience | 17 Years |
| Location | 1025 Executive Drive, Hixson, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285841254 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2018 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Erlanger Medical Center | Chattanooga, TN | Hospital |
| Memorial Healthcare System, Inc | Chattanooga, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Chattanooga Hamilton County Hospital Authority | 0547179731 | 156 |
| Erlanger Health | 1153780226 | 352 |
News Archive
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa's "exon skipping" platform and the ongoing relationship.
Cambridge Heart, Inc., today reported results for the three and six months ended June 30, 2010. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which is expected to be filed with the Securities and Exchange Commission on August 16, 2010.
The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE, a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce the clinical protocol is in the process of being approved. It is known that the Hepatitis A will be included in the Expanded Programme on Immunization (EPI) in 2010.
Bioanalytical Systems, Inc. today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.
› Verified 3 days ago
| Entity Name | Chattanooga Hamilton County Hospital Authority |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154751931 PECOS PAC ID: 0547179731 Enrollment ID: O20040302001086 |
News Archive
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa's "exon skipping" platform and the ongoing relationship.
Cambridge Heart, Inc., today reported results for the three and six months ended June 30, 2010. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which is expected to be filed with the Securities and Exchange Commission on August 16, 2010.
The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE, a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce the clinical protocol is in the process of being approved. It is known that the Hepatitis A will be included in the Expanded Programme on Immunization (EPI) in 2010.
Bioanalytical Systems, Inc. today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.
› Verified 3 days ago
| Entity Name | Erlanger Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477256303 PECOS PAC ID: 1153780226 Enrollment ID: O20230707000849 |
News Archive
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa's "exon skipping" platform and the ongoing relationship.
Cambridge Heart, Inc., today reported results for the three and six months ended June 30, 2010. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which is expected to be filed with the Securities and Exchange Commission on August 16, 2010.
The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE, a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce the clinical protocol is in the process of being approved. It is known that the Hepatitis A will be included in the Expanded Programme on Immunization (EPI) in 2010.
Bioanalytical Systems, Inc. today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brent Jeremy Campbell, DO 975 E 3rd St, Attn: Provider Enrollment, Chattanooga, TN 37403-2147 Ph: (423) 778-5630 | Dr Brent Jeremy Campbell, DO 1025 Executive Drive, Suite 100, Hixson, TN 37343 Ph: (423) 778-9030 |
News Archive
Prosensa, the Dutch biopharmaceutical company focusing on RNA modulating therapeutics, announces the initiation of two further programmes under its existing alliance with GSK covering novel RNA-based treatments for Duchenne Muscular Dystrophy (DMD). The initiation of these additional programs under the terms of the existing alliance agreement is a validation of both the potential of Prosensa's "exon skipping" platform and the ongoing relationship.
Cambridge Heart, Inc., today reported results for the three and six months ended June 30, 2010. Full financial statements and corresponding commentary can be found in the Company's Form 10-Q, which is expected to be filed with the Securities and Exchange Commission on August 16, 2010.
The Massachusetts General Hospital (MGH) Bipolar Clinic and Research Program with the Bipolar Trials Network is launching Bipolar CHOICE, a 10-site nationwide trial evaluating the real-world advantages and disadvantages of quetiapine, a widely prescribed second generation antipsychotic mood stabilizing medication, compared to lithium, the gold standard mood stabilizer, for the treatment of outpatients with bipolar disorder.
HTDS www.htdsmedical.com (HTDS) - The issuer's China based operating subsidiary Mellow Hope www.mellowhope.com is pleased to announce the clinical protocol is in the process of being approved. It is known that the Hepatitis A will be included in the Expanded Programme on Immunization (EPI) in 2010.
Bioanalytical Systems, Inc. today announced financial results for the fourth quarter and fiscal 2013, highlighted by net income of $252,000, or $0.03 per diluted share, for the fourth quarter and $773,000, or $0.09 per diluted share, for the year. This compares to net losses of $2,696,000, or $0.36 per share and $6,317,000, or $0.88 per share, for the fourth quarter and fiscal 2012.
› Verified 3 days ago
Dr. James J O'connell, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2051 Hamill Rd, Suite 301, Hixson, TN 37343 Phone: 423-877-1249 Fax: 423-870-2765 | |
Dr. Owen F Speer, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2051 Hamill Road Suite 301, Hixson, TN 37343 Phone: 423-877-1249 Fax: 423-870-2765 | |
Charles Gober, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 4980 Alpha Ln, Hixson, TN 37343 Phone: 423-870-2450 Fax: 423-877-5208 | |
Dr. Terri R Brunvoll, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1025 Executive Dr, Suite 100, Hixson, TN 37343 Phone: 423-870-2030 Fax: 423-875-6405 | |
Mark Thomas Simpson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4513 Hixson Pike, Suite 102, Hixson, TN 37343 Phone: 423-877-7999 Fax: 423-877-7901 | |
Dr. Ronald Wesley Jarl, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4980 Alpha Ln, Hixson, TN 37343 Phone: 423-870-2450 Fax: 423-877-5208 |